immuno-gene therapy and molecularly-targeted agent for head and neck squamous cell carcionma
| Project/Area Number |
15K10820
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
nakano hiroshi 京都府立医科大学, 医学(系)研究科(研究院), 講師 (00405309)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | サイトカイン / 頭頸部扁平上皮癌 / 免疫遺伝子治療 / セツキシマブ / 分子標的薬 / 頭頸部癌 / 扁平上皮癌 |
|---|
| Outline of Final Research Achievements |
We confirmed that IL-21, IL-27, IL-28 expression gene can suppress SCCVII tumor growth with in vivo electroporation method.
Moreover, we elucidated that combination therapy with Cetuximab and IL-21 or IL-28 can synergistically suppress tumor growth.
In order to elucidate the mechanism, we analyzed cytotoxic activity of NK cell and CTL, but significant difference could not be apparent.
|
Report
(4 results)
Research Products
(1 results)
